Tango Therapeutics, Inc.

TNGX Healthcare Biotechnology

Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024. In the quarter to June 2026, revenue fell 100.0%, EPS fell 5.71% and free cash flow fell 4.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

22.04 0.66 −2.91%
Market cap
$3.8B
P/E
0.0×
Fwd P/E
−15.3×
Dividend yield
—
F-score
4/9
Altman Z
9.88
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 4 — —
ROE
(51.65%) (37.23%) (38.42%) (21.34%)
ROA
(35.74%) (28.41%) (30.20%) (18.86%)
ROIC
(1,015.30%) (2,661.91%) (629.60%) (808.35%)
Return on Tangible Assets
(65.83%) (29.97%) (27.90%) (12.16%)
Average Days of Receivables
0.00 0.00 — —
Free Cash Flow per Share
(1.32) (1.20) (0.99) (0.96)
Free Cash Flow
(146.76) (139.93) (142.54) (144.25)
Other line items

Show all line items

Columns are period end dates